Does Performing a Confirmatory Tumour Biopsy in Patients with Metastatic Breast Cancer Alter their Management? The DESTINY Trial
The study aims to determine whether confirmatory biopsy at any point in a patient’s metastatic disease course, not just at diagnosis, alters patient management in women with metastatic breast cancer. It will also prospectively evaluate the impact of intervening lines of palliative systemic therapy (endocrine or chemotherapy) on the degree of discordance between ER, PR, and HER2 receptor status in the primary and metastatic tumours. This study may potentially change the approach to diagnosis and management of metastatic disease in breast cancer patients and may contribute to the development of a new standard of practice in the care of these patients. This study will also aid in determining the feasibility and patient acceptance of performing biopsies in all patients presenting with metastatic disease and allow investigators to explore the fundamental mechanisms of metastasis development where additional tissue is available that is not required for the primary endpoint of the study.
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society